Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mao Okada, Wan Wang, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi
Format: Artigo
Idioma:anglès
Publicat: 2020
Accés en línia:https://doi.org/10.1371/journal.pone.0231828
https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0231828/1/pone.0231828.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210221%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210221T143530Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!